<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20092609</article-id><article-id pub-id-type="pmc">2875491</article-id><article-id pub-id-type="publisher-id">cc8211</article-id><article-id pub-id-type="doi">10.1186/cc8211</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Lorente</surname><given-names>Leonardo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lorentemartin@msn.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Mart&#x000ed;n</surname><given-names>Mar&#x000ed;a M</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>marmartin@gmail.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Sol&#x000e9;-Viol&#x000e1;n</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jsolvio@gobiernodecanarias.org</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Blanquer</surname><given-names>Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>blanquer_jos@gva.es</email></contrib><contrib contrib-type="author" id="A5"><name><surname>P&#x000e1;ramo</surname><given-names>Jos&#x000e9; Antonio</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>japaramo@unav.es</email></contrib></contrib-group><aff id="I1"><label>1</label>Intensive Care Unit, Hospital Universitario de Canarias, Ofra s/n. La Cuesta, La Laguna 38320, Santa Cruz de Tenerife, Spain</aff><aff id="I2"><label>2</label>Intensive Care Unit. Hospital Universitario Nuestra Se&#x000f1;ora de Candelaria. Crta del Rosario s/n. Santa Cruz de Tenerife - 38010. Spain</aff><aff id="I3"><label>3</label>Intensive Care Unit. Hospital Universitario Dr. Negr&#x000ed;n. Barranco de la Ballena s/n. Las Palmas de Gran Canaria - 35010. Spain</aff><aff id="I4"><label>4</label>Intensive Care Unit. Hospital Cl&#x000ed;nico Universitario de Valencia. Avda. Blasco Ib&#x000e1;&#x000f1;ez n&#x000b0;17-19. Valencia - 46004. Spain</aff><aff id="I5"><label>5</label>Atherosclerosis Research Laboratory. CIMA-University of Navarra. Avda P&#x000ed;o XII n&#x000b0;55. Pamplona - 31008. Spain</aff><pub-date pub-type="ppub"><year>2010</year></pub-date><pub-date pub-type="epub"><day>19</day><month>1</month><year>2010</year></pub-date><!-- PMC Release delay is 12 months and 0 days and was based on the epub date.--><pub-date pub-type="pmc-release"><day>19</day><month>1</month><year>2011</year></pub-date><volume>14</volume><issue>1</issue><fpage>402</fpage><lpage>402</lpage><permissions><copyright-statement>Copyright &#x000a9;2010 BioMed Central Ltd</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>BioMed Central Ltd</copyright-holder></permissions><self-uri xlink:href="http://ccforum.com/content/14/1/402"/><abstract><sec><title/></sec></abstract></article-meta><notes><p>See related commentary by Hoffmann <italic>et al.</italic>, <ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/13/6/1006">http://ccforum.com/content/13/6/1006</ext-link></p></notes></front><body><sec><title/><p>We read with interest the commentary by Hoffmann and colleagues [<xref ref-type="bibr" rid="B1">1</xref>] on our manuscript recently published in <italic>Critical Care </italic>showing that matrix metalloproteinase (MMP)-9, MMP-10 and tissue inhibitor of matrix metalloproteinases (TIMP)-1 could be new biomarkers of severity and mortality in sepsis [<xref ref-type="bibr" rid="B2">2</xref>]. As they stated, the lack of serial measurements of MMPs and TIMPs over clinical evolution was as a limitation of our study. Despite this limitation, our results suggest that MMPs and TIMPs may be of pathophysiological significance in sepsis.</p><p>Some clinical studies have found higher circulating levels of MMP-9 [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>] and TIMP-1 [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>] in septic patients than in healthy controls, and higher levels of TIMP-1 [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>] or MMP-9 [<xref ref-type="bibr" rid="B4">4</xref>] in nonsurviving than in surviving septic patients. Our study also reports, for the first time, that MMP-10 circulating levels are also elevated in septic patients [<xref ref-type="bibr" rid="B2">2</xref>]. According to the results of some <italic>in vitro </italic>studies, MMP-10 could play a role in infection, since increased MMP-10 gene transcription was observed after infective stimulation of human and mice cells.</p><p>On the other hand, we think the correlation between MMP-9, TIMP-1 and markers of coagulopathy, and the lower MMP-9/TIMP-1 ratio in nonsurviving than in surviving septic patients found in our study, may be associated with a higher prothrombotic/antifibrinolytic state, responsible for the capillary thrombosis, multiple organ dysfunction, and death.</p><p>Finally, from a therapeutic perspective, the development of modulators of MMP/TIMP activity could be used as a new class of drugs for the treatment of severe sepsis [<xref ref-type="bibr" rid="B5">5</xref>].</p></sec><sec><title>Abbreviations</title><p>MMP: matrix metalloproteinase; TIMP: tissue inhibitor of matrix metalloproteinases.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></body><back><sec><title>Acknowledgements</title><p>The present study was supported, in part, by a grant from the Canary Islands Foundation for Health and Research (FUNCIS number PI 42/07) (Tenerife, Spain), by a grant from the Working Group on Infectious Diseases of the Spanish Society of Intensive Medicine, Critical Care, and Coronary Units (GTEI-SEMICYUC-2009), by funding from the Rafael Clavijo Foundation for Biomedical Research (Tenerife, Spain) and by the UTE project CIMA (University of Navarra, Spain).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Brueckmann</surname><given-names>M</given-names></name><name><surname>Borggrefe</surname><given-names>M</given-names></name><article-title>Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>1006</fpage><pub-id pub-id-type="doi">10.1186/cc8156</pub-id><pub-id pub-id-type="pmid">20017890</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Lorente</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>MM</given-names></name><name><surname>Labarta</surname><given-names>L</given-names></name><name><surname>Diaz</surname><given-names>C</given-names></name><name><surname>Sole-Violan</surname><given-names>J</given-names></name><name><surname>Blanquer</surname><given-names>J</given-names></name><name><surname>Orbe</surname><given-names>J</given-names></name><name><surname>Rodriguez</surname><given-names>JA</given-names></name><name><surname>Jimenez</surname><given-names>A</given-names></name><name><surname>Borreguero-Leon</surname><given-names>JM</given-names></name><name><surname>Belmonte</surname><given-names>F</given-names></name><name><surname>Medina</surname><given-names>JC</given-names></name><name><surname>Lliminana</surname><given-names>MC</given-names></name><name><surname>Ferrer-Aguero</surname><given-names>JM</given-names></name><name><surname>Ferreres</surname><given-names>J</given-names></name><name><surname>Mora</surname><given-names>ML</given-names></name><name><surname>Lubillo</surname><given-names>S</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Barrios</surname><given-names>Y</given-names></name><name><surname>Sierra</surname><given-names>A</given-names></name><name><surname>Paramo</surname><given-names>JA</given-names></name><article-title>Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>R158</fpage><pub-id pub-id-type="pmid">19799791</pub-id><pub-id pub-id-type="doi">10.1186/cc8115</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>U</given-names></name><name><surname>Bertsch</surname><given-names>T</given-names></name><name><surname>Dvortsak</surname><given-names>E</given-names></name><name><surname>Liebetrau</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>S</given-names></name><name><surname>Liebe</surname><given-names>V</given-names></name><name><surname>Huhle</surname><given-names>G</given-names></name><name><surname>Borggrefe</surname><given-names>M</given-names></name><name><surname>Brueckmann</surname><given-names>M</given-names></name><article-title>Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis</article-title><source>Scand J Infect</source><year>2006</year><volume>38</volume><fpage>867</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">17008230</pub-id><pub-id pub-id-type="doi">10.1080/00365540600702058</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Ebihara</surname><given-names>I</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Shoji</surname><given-names>H</given-names></name><name><surname>Koide</surname><given-names>H</given-names></name><article-title>Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment</article-title><source>Am J Med Sci</source><year>1998</year><volume>316</volume><fpage>355</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1097/00000441-199812000-00001</pub-id><pub-id pub-id-type="pmid">9856688</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Ashok</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Tracey</surname><given-names>KJ</given-names></name><name><surname>Sama</surname><given-names>AE</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><article-title>Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers</article-title><source>Mol Med</source><year>2009</year><volume>15</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">19593412</pub-id></mixed-citation></ref></ref-list></back></article>